Sign in

Keith Hornberger

@krhornberger.bsky.social
2.4K followers 119 following 1.4K posts

med chem @ Arvinas | PhD @ Columbia | hiker | cocktail enthusiast | he/him/huz/dad | dreaming of Sedona | while I have a connection to Arvinas, all opinions expressed are my own and do not represent the views, opinions, or positions of the company

PostsRepliesMedia
Keith Hornberger @krhornberger.bsky.social · 5h
It’s that time of year once more! Who will win the 2026 Nobel Prize in Chemistry? Wrong answers only.
static.klipy.com
Simpsons Wrong Answer Button
ALT: Simpsons Wrong Answer Button
4102
Keith Hornberger @krhornberger.bsky.social · 02/10/2026
We’re hiring in discovery chemistry! Come join our amazing team.
job-boards.greenhouse.io
Medicinal Chemistry Project Leader
Remote, Hybrid, New Haven - CT
11213
Keith Hornberger @krhornberger.bsky.social · 02/10/2026
The pepper crop has been suuuuuper late in Connecticut this year. I’m finally harvesting an increasing number of habañeros — in October! Will see how many more I can get before frost, which could be as soon as mid-next week
010
Keith Hornberger @krhornberger.bsky.social · 20/09/2026
Targeting Multiple KRAS Mutations with High-Affinity Macrocyclic Inhibitors: From Discovery to Preclinical Validation
pubs.acs.org
Targeting Multiple KRAS Mutations with High-Affinity Macrocyclic Inhibitors: From Discovery to Preclinical Validation
Abstract. The RAS Switch-II pockets’ discovery enabled targeting a challenging molecular site. Covalent KRASG12C inhibitors inspired efforts to find compou
140
Keith Hornberger @krhornberger.bsky.social · 21/08/2026
Garden is in full production mode today. Giant cucumbers and finally pulling some baby butternut squash
020
Keith Hornberger @krhornberger.bsky.social · 21/08/2026
Antibody-Mediated Delivery of BRM/BRG1 Protein Degraders Affords Strong Antitumor Efficacy in Multiple BRM-Dependent Non-Small Cell Lung Cancer Xenograft Models
pubs.acs.org
Antibody-Mediated Delivery of BRM/BRG1 Protein Degraders Affords Strong Antitumor Efficacy in Multiple BRM-Dependent Non-Small Cell Lung Cancer Xenograft Models
Abstract. The synthesis and biological characterization of multiple degrader antibody conjugates (DACs) bearing a heterobifunctional VHL-dependent proteoly
010
Keith Hornberger @krhornberger.bsky.social · 09/08/2026
Identification and SAR optimization of FBXO22-mediated TEAD Targeted Glue™ degraders
biorxiv.org
Identification and SAR optimization of FBXO22-mediated TEAD Targeted Glue™ degraders
TEAD transcription factors are emerging oncology targets due to their function as key effectors of the Hippo signalling pathway, which is frequently dysregulated in cancer. Here, we report the discove...
040
Keith Hornberger @krhornberger.bsky.social · 07/08/2026
Dual E3 ligase recruitment by monovalent degraders for tunable SMARCA 2/4 degradation
nature.com
Dual E3 ligase recruitment by monovalent degraders for tunable SMARCA 2/4 degradation - Nature Chemical Biology
The authors identified a series of covalent, monovalent glue degraders that can co-opt two E3 ligases, DCAF16 and FBXO22, in a parallel fashion to degrade SMARCA2/4 and demonstrated that ligase prefer...
031
Keith Hornberger @krhornberger.bsky.social · 06/08/2026
Interface Architecture of a VHL-PROTAC Complex with and without Cullin‑2
pubs.acs.org
Interface Architecture of a VHL-PROTAC Complex with and without Cullin-2
Abstract. Proteolysis Targeting Chimeras (PROTACs) are bispecific molecules that link a target protein to an E3 ligase, leading to ubiquitination and subse
000
Keith Hornberger @krhornberger.bsky.social · 06/08/2026
Spelling Bee’s frontal assault on thermodynamics continues
060
Keith Hornberger @krhornberger.bsky.social · 01/08/2026
Discovery of molecular glues that bind FKBP12 and structurally distinct targets using DNA-encoded libraries
nature.com
Discovery of molecular glues that bind FKBP12 and structurally distinct targets using DNA-encoded libraries - Nature Communications
In this study, authors screen a 3.2 million member FKBP scaffold-directed DNA-encoded library and identify FKBP12-binding molecular glues for both bromodomain-containing protein 9 (BRD9) and quinoid d...
0104
Keith Hornberger @krhornberger.bsky.social · 31/07/2026
Harnessing FBXO31 with Terminal Amide-Functionalized Molecules for Targeted Protein Degradation
pubs.acs.org
Harnessing FBXO31 with Terminal Amide-Functionalized Molecules for Targeted Protein Degradation
Abstract. Targeted protein degradation (TPD) is a powerful strategy for controlling protein abundance. Here, we establish FBXO31 as a TPD-competent E3 liga
010
Keith Hornberger @krhornberger.bsky.social · 29/07/2026
Identification of E3 ligase substrates and PROTAC-induced ubiquitylation sites using proximity-based identification of ubiquitin sites (PrIUS)
nature.com
Identification of E3 ligase substrates and PROTAC-induced ubiquitylation sites using proximity-based identification of ubiquitin sites (PrIUS) - Communications Biology
Proximity-dependent biotinylation coupled with ubiquitin remnant enrichment identifies PROTAC-induced ubiquitylation sites and E3 ligase substrates.
060
Keith Hornberger @krhornberger.bsky.social · 26/07/2026
Paul Workman was looking for more cocktail posts at AACR D3, so in honor of my recent vacation to Greece, here’s the Marvin’s Last Word: equal parts (3/4 oz) lime juice, gin, green Chartreuse, and mastiha (in place of the usual maraschino) + lime twist. Lovely.
010
Keith Hornberger @krhornberger.bsky.social · 16/07/2026
Spotted today in Litochoro, Greece - near Mount Olympus @chemjobber.bsky.social
180
Keith Hornberger @krhornberger.bsky.social · 18/06/2026
@danetteldaniels.bsky.social @georgwinter.bsky.social uh-oh…
120
Keith Hornberger @krhornberger.bsky.social · 17/06/2026
Bellerophon: An Automated Tool for PROTAC Decomposition
pubs.acs.org
Bellerophon: An Automated Tool for PROTAC Decomposition
Proteolysis-targeting chimeras (PROTACs) represent a promising modality for targeted protein degradation, yet their structural complexity complicates systematic design and analysis. Bellerophon is a n...
011
Keith Hornberger @krhornberger.bsky.social · 12/06/2026
The Contribution of Native Protein Complexes to Targeted Protein Degradation
pubs.acs.org
The Contribution of Native Protein Complexes to Targeted Protein Degradation
Targeted protein degradation (TPD) destroys proteins of interest (POIs) by hijacking the cellular proteolytic machinery. Most proteins in cells exist and function as part of multiprotein or macromolecular complexes, thereby allowing a single protein to control multiple biological processes. Therefore, when a small molecule degrader induces the proximity between an E3 ligase and the POI, the macromolecular context of the POI potentially influences the degradation outcomes of the POI and of the complex components. Here, we explore the degradation of the eight CK1α-SACK1 (formerly known as FAM83A-H) complexes initiated by molecular glue degraders primarily designed to target Ser/Thr kinase CK1α. We demonstrate that lenalidomide-derived degraders DEG-77 and SJ3149, which selectively target the CK1α isoform, codegrade multiple SACK1 proteins. We show that the degradation of SACK1 proteins by DEG-77 and SJ3149 requires CK1α, the CUL4ACRBN E3 ligase complex, and the proteasome. In cells derived from palmoplantar keratoderma patients harboring the CK1α-binding-deficient SACK1GR265P mutation, DEG-77 targets CK1α and mitotic SACK1D but not SACK1GR265P, highlighting the requirement for CK1α-SACK1 interaction to achieve codegradation. Our study underscores the importance of POI context in TPD and reinforces the potential for selectively targeting specific protein complexes for degradation.
020
Keith Hornberger @krhornberger.bsky.social · 11/06/2026
From KRASG12D to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design
pubs.acs.org
From KRASG12D to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design
KRAS, a significant oncology target, has been challenging to develop drugs for until recent discoveries of KRASG12C mutant-specific covalent inhibitors, including MK-1084. This article describes efforts toward the discovery of KRASG12D mutant-specific inhibitors and how synthetic innovations and structure-based drug design were utilized to facilitate the discovery of pan-KRAS inhibitors.
060
Keith Hornberger @krhornberger.bsky.social · 08/06/2026
Folks - little help for my kid on his Sociology final project. If you’ve got a spare 1-2 minutes, please take his short survey on AI usage. Trying to help him get a sample of more than just HS kids.
docs.google.com
Sociology - AI Usage Survey
Responses are anonymous; please answer as honestly as possible.
165
Keith Hornberger @krhornberger.bsky.social · 07/06/2026
Pine Knob Loop in Sharon, CT. In just 2.5 mi and a fairly challenging 710’ vertical, you get awesome views of the Litchfield Hills, a short sojourn on the AT, a (dry-ish) waterfall, mountain laurel in full bloom, and… 90 minutes of solitude to recharge.
050
Keith Hornberger @krhornberger.bsky.social · 05/06/2026
New PROTAC Designs for Targeted Protein Degradation in 2021–2025: Novel E3 Ligases and Pre-PROTACs
pubs.acs.org
New PROTAC Designs for Targeted Protein Degradation in 2021–2025: Novel E3 Ligases and Pre-PROTACs
Proteolysis-targeting chimeras (PROTACs) have emerged as a transformative paradigm in pharmaceutical research. Despite significant progress in PROTACs, they are overwhelmingly dominated by the recruitment of a very restricted subset of canonical E3 ligases (e.g., CRBN and VHL), which hinders their potential therapeutic applications. As a result, recent developments have led to the emergence of PROTACs that utilize nonclassical E3 ligases. Another challenge is systemic toxicity caused by degradation on-target degradation in nonintended tissues, prompting the development of pre-PROTACs to achieve conditional and spatiotemporal modulation of target protein levels. Herein, we provide a comprehensive summary and discussion of recent advancements in PROTACs based on “novel” E3 ligases, as well as PROTAC prodrugs activated by external stimuli and the tumor microenvironment, highlighting prospects for the design of effective and selective PROTACs.
030
Keith Hornberger @krhornberger.bsky.social · 04/06/2026
Discovery and Evaluation of a PROTAC Degrader Targeting SAMHD1 for the Treatment of Pulmonary Fibrosis
pubs.acs.org
Discovery and Evaluation of a PROTAC Degrader Targeting SAMHD1 for the Treatment of Pulmonary Fibrosis
SAMHD1 regulates intracellular nucleotide pool composition, and its overexpression is linked to tumor resistance to nucleoside drugs, organ injury, and fibrosis. Existing SAMHD1 inhibitors only exhibi...
020
Keith Hornberger @krhornberger.bsky.social · 03/06/2026
Evaluation of Oral PROTAC Guidelines: Efflux Ratio Outweighs Chameleonicity Descriptors
pubs.acs.org
Evaluation of Oral PROTAC Guidelines: Efflux Ratio Outweighs Chameleonicity Descriptors
Oral bioavailability of PROTACs, which often fall outside the Rule-of-Five space, is still not perfectly understood. Thus, the design of orally bioavailable PROTACs remains challenging. Chameleonicity...
030
Keith Hornberger @krhornberger.bsky.social · 28/05/2026
Expanding the targeted protein degradation approach with small molecule chimeras directed to the 26S proteasome
nature.com
Expanding the targeted protein degradation approach with small molecule chimeras directed to the 26S proteasome - Nature Communications
Targeted Protein Degradation (TPD) relies on the binding of specific targets and E3 ubiquitin-ligases to promote ubiquitination and degradation of targets by the proteasome. Here, by designing chimera...
010
Keith Hornberger @krhornberger.bsky.social · 27/05/2026
Hsp70-Targeting Chimeras Enable Dual Proteasomal and Lysosomal Degradation of Intracellular and Extracellular Proteins
pubs.acs.org
Hsp70-Targeting Chimeras Enable Dual Proteasomal and Lysosomal Degradation of Intracellular and Extracellular Proteins
Developing targeted protein degradation (TPD) strategies with disease-specific mechanisms, modularity, and facile designability could ensure drug efficacy and selectivity. Herein, a small-molecule, Hs...
031
Keith Hornberger @krhornberger.bsky.social · 25/05/2026
A dihydrouracil CRBN ligand mitigates IMiD associated safety liabilities in heterobifunctional targeted protein degrader
nature.com
A dihydrouracil CRBN ligand mitigates IMiD associated safety liabilities in heterobifunctional targeted protein degrader - Nature Communications
IMiD-based PROTACs may degrade IKZF1/3 with hematologic effects. This study profiles these liabilities using hematopoietic assays showing stem cell rewiring and interferon activation and introduces a ...
000
Keith Hornberger @krhornberger.bsky.social · 16/05/2026
Bluebird day in the Litchfield Hills. Prospect Mountain Preserve, 3.8 mi and 660’ vertical. And two hours of blessed solitude.
140
Keith Hornberger @krhornberger.bsky.social · 01/05/2026
Discovery of a Selective DNMT1 Degrader with a Unique Molecular Glue Mechanism as a Potential Therapeutic Agent for Acute Myeloid Leukemia
pubs.acs.org
Discovery of a Selective DNMT1 Degrader with a Unique Molecular Glue Mechanism as a Potential Therapeutic Agent for Acute Myeloid Leukemia
Previous research indicated that DNA methyltransferase 1 (DNMT1) inhibitors can induce UHRF1-mediated degradation of the DNMT1 protein. However, the underlying degradation mechanism remains poorly und...
010
Keith Hornberger @krhornberger.bsky.social · 28/04/2026
Discovery of SD-965 as a Potent, Selective, and Efficacious STAT3 PROTAC Degrader
pubs.acs.org
Discovery of SD-965 as a Potent, Selective, and Efficacious STAT3 PROTAC Degrader
Signal transducer and activator of transcription 3 (STAT3) is a promising therapeutic target for human cancers and other human diseases. Herein, we report on the design, synthesis, and evaluation of n...
062
Keith Hornberger @krhornberger.bsky.social · 22/04/2026
Adios, San Diego - until we meet again. An awesome #AACR26 is in the books, and I’m on an airplane back to dreary northeastern spring
030
Keith Hornberger @krhornberger.bsky.social · 21/04/2026
At an undisclosed location
020
Keith Hornberger @krhornberger.bsky.social · 20/04/2026
Third up at today’s #AACR26 NDoH, J&J reported on their ENPP3 ADC JNJ-89862175. All slides were “do not post” so you can use your imagination
010
Keith Hornberger @krhornberger.bsky.social · 20/04/2026
Next up at #AACR26 NDoH, Amphista disclosed their BRD9 degrader AMX-883
151
Keith Hornberger @krhornberger.bsky.social · 20/04/2026
The final New Drugs on the Horizon session at #AACR26 is underway. It kicked off with Circle’s disclosure of their macrocyclic cyclin A/B inhibitor CID-078
040
Keith Hornberger @krhornberger.bsky.social · 20/04/2026
Rounding out the second of three #AACR26 NDoH sessions, AstraZeneca disclosed a CD30 dual payload ADC
120
Keith Hornberger @krhornberger.bsky.social · 20/04/2026
Next up at #AACR26 NDoH, Triana disclosed TRI-611, a molecular glue degrader of ALK
051
Keith Hornberger @krhornberger.bsky.social · 19/04/2026
Next at #AACR26 NDoH, Novartis disclosed their CDK2 inhibitor ECI830
020
Keith Hornberger @krhornberger.bsky.social · 19/04/2026
Second New Drugs on the Horizon is off and running at #AACR26. First up, Palleon disclosed their targeted sialidase E-688/HLX316.
130
Keith Hornberger @krhornberger.bsky.social · 19/04/2026
Rounding out the first of three NDoH sessions at #AACR26, EpiBiologics disclosed EPI-326, a bispecific antibody degrader of EGFR. All slides are DO NOT POST. We’re headed into a 30 min break before the second session starts.
020
Keith Hornberger @krhornberger.bsky.social · 19/04/2026
Next up at #AACR26 NDoH, Tango Therapeutics disclosed TNG961, a molecular glue degrader of HBS1L
030
Keith Hornberger @krhornberger.bsky.social · 19/04/2026
Next at #AACR26 NDoH, AstraZeneca disclosed AZD8359, a CD8-biased T cell engager.
040
Keith Hornberger @krhornberger.bsky.social · 19/04/2026
At #AACR26 New Drugs on the Horizon, Phil Chamberlain from Neomorph just disclosed the structure of their ARNT molecular glue degrader NEO-811. Unfortunately all slides were “do not post” so you’ll just have to wait for someone to draw it out.
130
Keith Hornberger @krhornberger.bsky.social · 19/04/2026
A random smattering from the many excellent educational sessions at #AACR26 today - I’ll let you figure out the context for each
030
Keith Hornberger @krhornberger.bsky.social · 18/04/2026
It’s go time #AACR26
020
Keith Hornberger @krhornberger.bsky.social · 18/04/2026
Hello San Diego! It’s late, but I’m here, and I missed you.
160
Keith Hornberger @krhornberger.bsky.social · 17/04/2026
Ok gang, I’m on my way to San Diego for #AACR26 - roll call! Who else is going? (btw I’ll live post a few things from the New Drugs on the Horizon session which are always a highlight for me)
230
Keith Hornberger @krhornberger.bsky.social · 10/04/2026
A Novel FXR-Targeted DUBTAC and Its Applications in Cholestasis Therapy
pubs.acs.org
000
Keith Hornberger @krhornberger.bsky.social · 08/04/2026
Normalizing Covalent Potency for Electrophilicity with Ligand Reactivity Efficiency (from my old BI amigo Brian Cook and colleagues)
pubs.acs.org
Normalizing Covalent Potency for Electrophilicity with Ligand Reactivity Efficiency
Covalent modalities represent an important component of the modern medicinal chemist’s toolbox for pursuing challenging targets in drug discovery. By taking a “covalent-first” approach to identifying ...
010
Keith Hornberger @krhornberger.bsky.social · 06/04/2026
DeepDegradome: A structure-aware deep learning framework for PROTAC and ligand generation against protein targets
pnas.org
PNAS
Proceedings of the National Academy of Sciences (PNAS), a peer reviewed journal of the National Academy of Sciences (NAS) - an authoritative source of high-impact, original research that broadly spans...
010